Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
PEGASUS-TIMI 54 STUDY SHOWS THAT LONG-TERM TREATMENT WITH BRILINTA REDUCED THROMBOTIC CARDIOVASCULAR EVENTS IN PATIENTS WITH A HISTORY OF HEART ATTACK Data from 21,000 patient study presented at...
-
FILING OF ANNUAL REPORT ON FORM 20-F WITH THE US SECURITIES AND EXCHANGE COMMISSION AstraZeneca PLC announced today that, on 10 March 2015, it filed its Annual Report on Form 20-F with the US...
-
ANNUAL FINANCIAL REPORT AstraZeneca PLC (the Company) announced today the publication of its Annual Report and Form 20-F Information 2014 (Annual Report). A copy of the Annual Report will be...
-
ASTRAZENECA TO PARTICIPATE IN US FDA ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE AstraZeneca today announced it will participate in the US Food and Drug Administration (FDA) Endocrinologic...
-
AstraZeneca COMPLETES acquiSITION OF rights to actavis' Branded respiratory portfolio in THE US AND CANADA Acquisition strengthens AstraZeneca's aclidinium respiratory franchise and adds immediate...
-
17 February 2015 AstraZeneca today announced that Dr Cornelia (Cori) Bargmann will be proposed to shareholders for election as a Non-Executive Director at the Company's Annual General Meeting (AGM)...
-
AstraZeneca has announced that the US District Court for the District of New Jersey ruled US Patent No. 7,524,834 ("the '834 patent"), protecting PULMICORT RESPULES in the US, is...
-
AstraZeneca to acquire rights to actavis' Branded respiratory portfolio in THE US AND CANADA Agreement strengthens AstraZeneca's aclidinium respiratory franchise and adds immediate revenues with...
-
Det finansiella resultatet för 2014 är i linje med den höjda prognosen som lämnades i samband med resultatet för tredje kvartalet 2014. · Intäkterna för helåret ökade med 3 % i fasta valutakurser...
-
AstraZeneca Fourth Quarter and Full Year Results 2014 On Thursday, 5 February 2015, AstraZeneca will release fourth quarter and full year results for 2014 at 07:00GMT. An analyst presentation...